The purpose of this study is to facilitate the consent, collection, and research use of biospecimens and data for profiling of immune cells and research from patients seen by physicians at Weill Cornell Medical College/New York-Presbyterian who are screened for, consented to, and undergo tumor-infiltrating lymphocyte (TIL) cellular therapy for solid tumor malignancies.
   
Patients will undergo surgery as part of standard of care surgical excision of tumor tissue either at the time of diagnosis, time of progression, time of TIL tissue harvest, or on subsequent progression as standard of care. At that time, if available, additional blood and tumor tissue will be obtained for research of blood, tumor tissue, or TIL samples following standard of care treatment. Blood will be obtained at various timepoints along the TIL treatment journey as part of standard of care blood draws.